Forte Biosciences releases detailed Phase 1b data showing FB102's statistically significant FVASI benefit over placebo and favorable safety in vitiligo patients
https://finviz.com/stock?t=FBRX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.